Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation
Julien Champagne(The Netherlands Cancer Institute), Reuven Agami(The Netherlands Cancer Institute), Marieke van de Ven(The Netherlands Cancer Institute), Natalie Proost(The Netherlands Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center), Yuval Malka(Hebrew University of Jerusalem), Johanna Olweus(Oslo University Hospital), Jasmine Montenegro Navarro(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Weiwen Yang(Oslo University Hospital), Remco Nagel(The Netherlands Cancer Institute), Rhianne Voogd(The Netherlands Cancer Institute), Adva Kochavi(The Netherlands Cancer Institute), Abhijeet Pataskar(The Netherlands Cancer Institute), Onno B. Bleijerveld(Oncode Institute), Domenica Lovecchio(The Netherlands Cancer Institute), Maarja Laos(University of Helsinki), Nadine Berenst(The Netherlands Cancer Institute), Xiaodong Feng(The Netherlands Cancer Institute), Morten M. Nielsen(Oslo University Hospital), Amos Fumagalli(Centre National de la Recherche Scientifique), Yingqian Li(Oslo University Hospital), Lorenzo Valcanover(The Netherlands Cancer Institute), Lisanne Giebel(The Netherlands Cancer Institute)
Cited by 13
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k